Related Experiment Video
Updated: Jun 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Patient perspectives on once-weekly medications for diabetes
W H Polonsky1, L Fisher, D Hessler
1Department of Psychiatry, University of California, San Diego, CA 92014, USA. whp@behavioraldiabetes.org
Diabetes, Obesity & Metabolism
|January 5, 2011
Summary
Patients with type 2 diabetes view once-weekly (QW) glucose-lowering medications positively, especially current injection users. Key benefits include convenience and improved quality of life, though concerns about cost and consistency exist.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Type 2 diabetes management often involves complex medication regimens.
- Patient adherence and quality of life are critical factors in treatment success.
- Once-weekly (QW) glucose-lowering medications offer a potential alternative to more frequent dosing.
Purpose of the Study:
- To investigate patient perspectives on once-weekly (QW) glucose-lowering medication options.
- To identify patient beliefs, preferences, and concerns regarding QW therapy.
- To explore factors influencing patient willingness to adopt injectable QW medications.
Main Methods:
- An anonymous online survey was administered to 1516 adults with type 2 diabetes.
- The survey assessed perceived attributes of QW therapy and willingness to use injectable QW medication.
- Patient characteristics, including glycemic control and diabetes quality of life (DQOL), were evaluated.
Main Results:
- Positive attitudes towards QW medications were prevalent, particularly among current injection users.
- Convenience, adherence, and improved quality of life (QOL) were commonly cited benefits.
- 46.8% of patients were willing to take an injectable QW medication; willingness increased with poorer DQOL and glycemic control.
Conclusions:
- Once-weekly (QW) glucose-lowering medications are generally viewed favorably by type 2 diabetes patients.
- Patient satisfaction with current treatment and prior injection experience significantly influence acceptance.
- Clinicians should discuss QW medication benefits and address patient concerns like cost and dosing consistency.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...